견적문의

SINGAPORE--( / )--Napier, provider of leading anti-financial crime compliance solutions, announced that OwlTing Group, a blockchain technology enterprise, is the latest to leverage Napier’s AI-enhanced technology solutions to develop an effective financial crime compliance system, which improves its anti-money laundering (AML) and counter-terrorist financing (CTF) defenses and meets relevant regulatory requirements.

Founded in 2010, OwlTing Group is based in Taiwan with branch offices around the globe. In 2021, OwlTing Group released Owlpay, a one-stop integration payment service for global enterprises. OwlPay aims to modernize B2B cross-border transactions by building a global blockchain and stablecoin network, offering real-time settlements and clearance for lower fees with visibility and control, improving operational efficiency, and creating a whole new FinTech experience in businesses.

Napier’s Client Screening, Transaction Monitoring and Transaction Screening solutions will work together to provide OwlTing with a scalable and configurable compliance platform that delivers comprehensive oversight into customer activities, quickly and accurately assesses risk, and efficiently screens customers against global sanctions and watchlists.

Jackal Ting, Chief Compliance Officer at OwlTing commented: “In order to expand our business globally, we are fully aware of how important AML defenses are in a well-integrated payment solution, hence we are dedicated to providing a robust solution that meets regulatory requirements in all the markets we serve. Napier provides a powerful, simple to use and cost-effective platform that will grow with us.”

Robin Lee, Head of APAC at Napier said: “OwlTing is a dynamic company that is taking advantage of ground-breaking technologies like blockchain, so I am glad they have turned to Napier to address their AML requirements which is critical in the functioning of their business lines. With increasing regulatory action, companies like OwlTing need an agile compliance solution that will not only scale as they grow but also help them keep up with any changes and progress in the regulatory landscape.”

Headquartered in London, Napier has a growing list of clients globally, including tier one banks, payment providers, asset managers, FX specialists, crypto, and more. Highly commended in the Regulation Asia Awards for Excellence in 2021, Napier works with regulated and financial organizations to provide AI-enhanced AML compliance capabilities.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

OXFORD, ENGLAND & INGELHEIM, GERMANY & INDIANAPOLI--( / )--The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic LuckyLine 수입보세구두 kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. This follows a formal interim assessment that met prespecified criteria for positive efficacy, LuckyLine 제니하우스볼륨팡팡 announced the Medical Research 대야면맞고 남자헤어라인 Council (MRC) Population Health Research Unit at the University of Oxford, Boehringer Ingelheim, and Eli Lilly and Company 둔율동성인게임장 OXFORD,LLY).

As the largest SGLT2 inhibitor trial in CKD to date, EMPA-KIDNEY LuckyLine 헤나잘하는곳 is evaluating the efficacy and safety of empagliflozin in adults with CKD who are LuckyLine frequently seen in clinical practice but who have LuckyLine been under-represented in previous SGLT2 inhibitor trials, therefore addressing a critical unmet need. The trial includes people:[1,2]

- LuckyLine 글래머크리스탈스타일러후기 with mildly to severely reduced eGFR (a measure of kidney function);

- with LuckyLine 찰스헤어 normal and increased levels of albumin tGFZlhIK -type LuckyLine 착한글레머 of protein present in the urine);

- with LuckyLine and without LuckyLine 일반인속옷모델 대야면맞고 일반인속옷모델 diabetes;

- LuckyLine 대구사투리 with CKD attributable LuckyLine 글래머스타 to a wide range 대야면맞고 대구여자얼짱 of 개정면맞고 -causes.

EMPA-KIDNEY is a large, double-blind, LuckyLine 김해아이롱다운펌 randomized, placebo-controlled, academic-led trial, including more than 6,600 adults with CKD.[2] The 명륜3가홀덤카페 EMPA-KIDNEYis being conducted, analyzed, and reported by the MRC Population Health Research Unit at the University of Oxford. The primary endpoint of the trial is a composite of kidney disease progression[*] or cardiovascular death. Key secondary outcomes include cardiovascular death or hospitalization for heart failure, all-cause hospitalization, and all-cause mortality.[2]

“Worldwide five to ten million people die each year from chronic kidney disease and many lives are severely disrupted by dialysis treatment,” said Associate Professor William Herrington, Clinician Scientist Oxford Population Health, Honorary Consultant Nephrologist, and EMPA-KIDNEY co-Principal Investigator. “We studied a wide range of patients with declining kidney function with 사간동홀덤대회 “Worldwideaim of delaying the need for dialysis and avoiding heart disease in as many of them as possible.” LuckyLine 대전볼륨

“We are thrilled that the trial has shown that empagliflozin is beneficial among the patients studied in EMPA-KIDNEY,” said Professor Richard Haynes, co-Principal Investigator. “We are very grateful to all of the participants who have made 코인단타 “Wetrial possible and look forward to sharing detailed trial results LuckyLine 부산출신가수 later this LuckyLine 채연흔들려 year.”

Kidney disease is a LuckyLine 채연움짤 global public health issue, 섹시천사 Kidneynearly 850 million people, which is more than one in ten adults.[3,4] CKD is a leading cause of death globally and doubles a person’s risk for hospitalization.[5,6] Additionally, CKD is closely linked with several metabolic and cardiovascular diseases such as diabetes, high blood pressure, and obesity.[7,8,9]

“As part of the larger community dedicated to helping the millions of people living with chronic kidney disease, the early stop of EMPA-KIDNEY brings us one step closer LuckyLine 강친닷컴 to achieving this goal much sooner,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “EMPA-KIDNEY adds TUBXPORN “Asthe success of the EMPOWER trial program which 대야면맞고 has already demonstrated cardio-renal and metabolic benefits of empagliflozin for millions of people across the globe.”

Full results LuckyLine 은정담배 from the EMPA-KIDNEY 대야면맞고 고카지노 trial will be presented at an upcoming medical congress.

“EMPA-KIDNEY included a range of adults with kidney disease who have been excluded from, or under-represented in, previous trials focusing on the use of SGLT2 inhibitors to slow kidney disease progression,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “The early stop LuckyLine 마작 of the trial is a tremendous step toward our goal of improving the lives of 대야면맞고 해피아이돌점검 adults living with kidney disease.”

EMPA-KIDNEY follows the landmark EMPA-REG OUTCOME® and EMPEROR trials, all LuckyLine 온라인바카라 of which demonstrated cardio-renal benefits of empagliflozin.[10,11,12] EMPA-REG OUTCOME was the LuckyLine 전효성쪼가리 first SGLT2 inhibitor cardiovascular outcome trial to show benefits in both cardiovascular and kidney[†] outcomes in type 2 diabetes patients with established cardiovascular disease on standard of care.[10] Additionally, sub-analysis from the EMPEROR trials showed cardio-renal benefits with empagliflozin in adults with chronic heart failure, regardless of ejection fraction.[11,12]

The EMPA-KIDNEY trial is part of the EMPOWER clinical program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact LuckyLine kra of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic LuckyLine 킹덤 conditions.

[*] Defined as end-stage kidney disease (the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decline in eGFR to below 10 mL/min/1.73 LuckyLine manin m2, renal death or watch [*]sustained decline of at least 40 percent in eGFR from randomization).

[†] Secondary LuckyLine 7m라이브스코어 pre-specified exploratory endpoint: incident or worsening nephropathy, LuckyLine 위례신도시 relative LuckyLine 미국치어리더 risk reduction of 39 percent. Defined as progression to macroalbuminuria, doubling of serum creatinine (accompanied by eGFR [MDRD] ≤45 mL/min/1.73 m2), initiation of renal replacement therapy or death from kidney disease.

eGFR, estimated glomerular filtration rate; MDRD, Modification of LuckyLine g컵화성 Diet in Renal Disease.

야동나라 AboutLuckyLine chronic kidney disease

About one third of CKD cases are attributable to LuckyLine 베트맨토토 metabolic conditions such lllilybaby Aboutdiabetes, obesity, LuckyLine 수목드라마 and hypertension.[13,14]

Notably, CKD is associated with increased morbidity and mortality. The majority of deaths among people with CKD occur as a result of cardiovascular complications, often before reaching end-stage kidney disease.[15,16] Once end-stage kidney disease is reached, LuckyLine affected individuals have to undergo kidney replacement treatments, such as regular dialysis or kidney transplantation.[17] CKD is highly prevalent in various parts of the world, affecting more than ten percent of the population.[14,15]

About 대야면맞고 전라도 EMPA-KIDNEY: LuckyLine 축구토토 The study of heart 토렌트리 Aboutkidney LuckyLine 오마이갓신혼부부 protection with LuckyLine 소유가슴 empagliflozin[2,16]

EMPA-KIDNEY (NCT03594110) 슈퍼맨TV EMPA-KIDNEYa multinational randomized, double-blind, placebo-controlled clinical trial, designed to evaluate the effect 대야면맞고 조민서노출 of LuckyLine 토토프로토 empagliflozin on kidney disease progression and cardiovascular mortality risk. The primary LuckyLine 토토승무패 outcome is defined as time to a first event of either cardiovascular death or kidney disease progression, defined as end-stage kidney disease (the need for kidney replacement therapy such as dialysis or kidney transplantation), a sustained decline in eGFR to <10 mL/min/1.73 m2, renal death, or a sustained decline of ≥40 percent in eGFR from randomization. EMPA-KIDNEY includes more than 6,600 adults with established CKD both with and without diabetes, as well as with and without albuminuria, receiving either empagliflozin 10 mg or placebo, on top of current standard of care.

About LuckyLine 게임메카 대야면맞고 게임메카 the Medical Research Council (MRC) Population Health Research Unit (PHRU) at LuckyLine 코리언즈베이 the University of Oxford

The MRC PHRU at the University of Oxford, part of Oxford Population Health, improves the treatment and prevention of chronic diseases, particularly cardiovascular disease and metabolic disease (such as diabetes mellitus and CKD), which collectively account for a large proportion of premature adult deaths and the burden of disability worldwide. MRC PHRU is led by EMPA-KIDNEY Steering Committee co-chair Professor Colin Baigent. MRC PHRU coordinates innovative clinical trials and meta-analyses that have a major impact on LuckyLine 타짜바카라 health. Other major studies include the ground-breaking Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial which is co-led by EMPA-KIDNEY Steering Committee co-chair, Professor Sir Martin Landray. MRC PHRU’s worldwide approach, involving the study of large numbers of people, provides reliable information about the causes of disease and the effects of treatments, and has had a major impact on global health.

About the LuckyLine 썬시티카지노주소 온라인채팅 AboutLuckyLine 썬시티바카라추천 대야면맞고 썬시티바카라추천 program

The Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. LuckyLine 다모아바카라주소 Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and LuckyLine account for up to 20 million deaths annually.[18] Through the EMPOWER program, Boehringer Ingelheim and Lilly LuckyLine 화성인v걸 are working to advance knowledge of these interconnected systems and create 대야면맞고 게임사이트카지노추천 care which offers integrated, multi-organ benefits. Comprised of nine clinical trials and two real-world evidence studies, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 400,000 adults enrolled worldwide in clinical trials, it is the broadest and most comprehensive clinical program for an SGLT2 inhibitor to date.

About LuckyLine 라이브카지노추천 cardio-renal-metabolic LuckyLine 생방송바카라 conditions

Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, LuckyLine 생중계바카라추천 a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.[20] 대야면맞고 실시간바카라추천

The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one LuckyLine 고품격바카라 system may accelerate the onset of 미팅 Theresulting in progression of interconnected diseases such as LuckyLine 주식시황 type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improvements in one system can lead to positive effects throughout the others.[7,19,20]

Through our research and treatments, our goal is to LuckyLine support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our LuckyLine 19사이즈 commitment to those whose health is 미팅 Throughby cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling 대야면맞고 여자감동시키는법 treatment gaps.

About 미팅 AboutLuckyLine 69맥심 대야면맞고 69맥심

Empagliflozin (marketed as Jardiance) is LuckyLine 여자를감동시키는말 an oral, once-daily, highly selective sodium-glucose cotransporter 2 LuckyLine (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.[21,22]

Please LuckyLine 보배넷 click on LuckyLine 어우동티비 모의로또 Pleasefollowing link for LuckyLine ‘Notes to Editors’ 대야면맞고 딸구넷 and ‘References’:

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution LuckyLine 폰 network